IP Library Granted Patent US 10,549,051
Granted Patent B2
US 10,549,051 · App. 15/871,665 · Granted Feb 4, 2020

System and method for infusion set dislodgement detection

Inventor: Michael Rosinko (Anaheim, CA)
Assignee: Tandem Diabetes Care, Inc.
A61M5/5086A61M5/16836A61M2205/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,549,051
App. No.
15/871,665
Granted
Feb 4, 2020
Kind
B2
Abstract

A portable insulin pump can utilize readings from a sensor incorporated into an infusion set used with the pump to deliver insulin to a patient to determine if the infusion set is or is likely to become dislodged from the patient. Readings from the sensor that are inconsistent with expected readings or a range of expected readings can indicate that the infusion set has become dislodged from the patient.

Claims (33)

1. A method of detecting dislodgement of an infusion set of a portable infusion pump, comprising:

receiving information obtained by a glucose sensor that obtains readings relating to glucose levels of a user;

determining, via a processor configured to determine from estimated glucose levels determined based on the sensor readings, that the glucose sensor has become dislodged from the user;

determining, based on the estimated glucose levels indicating dislodgement of the glucose sensor, that a cannula fluidly connected to a portable infusion pump the portable infusion pump to deliver medicament to the user is or is likely to become dislodged from the user; and

notifying the user of potential dislodgement of the cannula from the user if it is determined that the cannula is or is likely to become dislodged.

2. The method of claim 1 , wherein notifying the user of potential dislodgement of the cannula provides the notification on a user interface of the portable infusion pump.

3. The method of claim 1 , wherein notifying the user of potential dislodgement of the cannula provides the notification on a user interface of a remote control device.

4. The method of claim 1 , wherein the glucose sensor and the cannula are mechanically linked to each other.

5. The method of claim 4 , wherein the cannula and the glucose sensor are mechanically linked to each other by both being connected to a patch adapted to retain the cannula in the user.

6. The method of claim 1 , wherein determining that the glucose sensor has become dislodged from the user includes determining that the estimate glucose levels are outside of an expected range relating to typical glucose levels.

7. The method of claim 1 , wherein determining that the glucose sensor has become dislodged from the user includes determining that one or more estimated glucose levels are above a high threshold or below a low threshold.

8. The method of claim 1 , further comprising discontinuing delivery of medicament with the portable infusion pump upon determining that the cannula is or is likely to become dislodged.

9. The method of claim 8 , further comprising:

receiving, after discontinuing delivery of medicament, an indication from the user that the cannula is properly attached to the user; and

reinitiating delivery of medicament with the portable infusion pump in response to the indication.

10. The method of claim 1 , wherein the glucose sensor and the cannula are configured for common transcutaneous insertion into the user at a single insertion location.

11. A method of delivering a medicament to a user with a portable infusion pump, comprising:

receiving information obtained by a glucose sensor that obtains readings relating to glucose levels of a user;

delivering a medicament to the user based on the information obtained by the glucose sensor;

determining, via a processor configured to determine from estimated glucose levels determined based on the sensor readings, that the glucose sensor has become dislodged from the user;

determining, based on the estimated glucose levels indicating dislodgement of the glucose sensor, that a cannula fluidly connected to a portable infusion pump the portable infusion pump to deliver medicament to the user is or is likely to become dislodged from the user; and

automatically discontinuing delivery of the medicament with the portable infusion pump upon determining that the cannula is or is likely to become dislodged.

12. The method of claim 11 , further comprising:

receiving, after discontinuing delivery of medicament, an indication from the user that the cannula is properly attached to the user; and

reinitiating delivery of medicament with the portable infusion pump in response to the indication.

13. The method of claim 11 , further comprising notifying the user of potential dislodgement of the cannula from the user if it is determined that the cannula is or is likely to become dislodged.

14. The method of claim 13 , wherein notifying the user of potential dislodgement of the cannula provides the notification on a user interface of the portable infusion pump.

15. The method of claim 13 , wherein notifying the user of potential dislodgement of the cannula provides the notification on a user interface of a remote control device.

16. The method of claim 11 , wherein the glucose sensor and the cannula are mechanically linked to each other.

17. The method of claim 16 , wherein the cannula and the glucose sensor are mechanically linked to each other by both being connected to a patch adapted to retain the cannula in the user.

18. The method of claim 11 , wherein determining that the glucose sensor has become dislodged from the user includes determining that the estimate glucose levels are outside of an expected range relating to typical glucose levels.

19. The method of claim 11 , wherein determining that the glucose sensor has become dislodged from the user includes determining that one or more estimated glucose levels are above a high threshold or below a low threshold.

20. The method of claim 11 , wherein the glucose sensor and the cannula are configured for common transcutaneous insertion into the user at a single insertion location.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Mar 24, 2024
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: TANDEM DIABETES CARE, INC.
Reel/Frame 066880/0918 →
SECURITY INTEREST Recorded May 25, 2022
From: TANDEM DIABETES CARE, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 060179/0100 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2018
From: ROSINKO, MICHAEL
To: TANDEM DIABETES CARE, INC.
Reel/Frame 044623/0201 →
Continuity (2)
Continuation 13923556 · Jun 21, 2013
Related Publication 20180193573A1 · Jul 12, 2018
Cited By (6)
US 12,251,536 US 12,318,578 US 12,431,104 US 12,564,677 US 12,567,494 US 12,653,968